Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.31 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24700866 | 0.97 | HRH3 (0.47) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL26194411 | 0.95 | HRH3 (0.46) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL25829852 | 0.91 | HRH3 (0.44) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL18898331 | 0.89 | HRH3 (0.40) | HRH3CCR2KCNH2 | |
| SCHEMBL21157892 | 0.87 | HRH3 (0.45) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL21660306 | 0.86 | HRH3 (0.40) | HRH3CCR2KCNH2 | |
| SCHEMBL25872792 | 0.86 | HRH3 (0.44) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL24256708 | 0.86 | HRH3 (0.44) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL20980172 | 0.84 | HRH3 (0.43) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL23920781 | 0.84 | HRH3 (0.43) | HRH3CCR2KCNH2CHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20210009542-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | ABBVIE INC. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009542-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | HRH3 4595/4885CCR2 1701/4885KCNH2 4867/4885 |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | RSU1, KRAS, NRAS | HRH3 2569/4885CCR2 2987/4885KCNH2 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.